ISRCTN ISRCTN15716557
DOI https://doi.org/10.1186/ISRCTN15716557
Secondary identifying numbers DG7T
Submission date
18/06/2018
Registration date
20/06/2018
Last edited
19/06/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Diabetes patients have impaired energy metabolism in the heart (cardiac energetics). This can be measured as low PCr/ATP. Heart and blood vessel (cardiovascular) disease is the most common cause of death in people living with type 2 diabetes, and there is no specific treatment for cardiovascular complications in diabetes.
Ketones can improve energy metabolism in the heart. TdeltaS Ltd has developed a ketone ester drink named DeltaG® which quickly and safely elevates ketone blood levels. It is already proven to be safe as a drink in healthy humans.
The aim of this trial is to investigate whether drinking a ketone solution can increase PCr/ATP levels in the hearts of healthy volunteers. The results will guide future studies in people with diabetes or heart failure.

Who can participate?
Healthy volunteers aged 18-70 years

What does the study involve?
The participants must fast (eat no food) for 24 hours. Drinking water is allowed and encouraged during the fast. They will then undergo an MRI scan before drinking a mix of 25 ml of a ketone monoester and water. They will have another MRI scan 30 minutes after drinking the ketone solution.

What are the possible benefits and risks of participating?
The ketone drink has a very bitter taste. It is safe to drink, but may cause mild headaches and abdominal cramps. The MRI scan is not painful and doesn't use radiation, however some people experience claustrophobia while being in the scanner. There are no expected benefits of taking part.

Where is the study run from?
The Oxford Centre for Functional MRI of the Brain (UK)

When is the study starting and how long is it expected to run for?
July 2018 to August 2019

Who is funding the study?
TdeltaS Ltd.

Who is the main contact?
Dr Adrian Soto.
adrian.soto@dpag.ox.ac.uk

Contact information

Dr Adrian Soto
Scientific

Sherrington Building
South Parks Road
Oxford
OX1 3PT
United Kingdom

Phone 01865 282248
Email adrian.soto@dpag.ox.ac.uk

Study information

Study designProspective open-label basic science study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeOther
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleThe acute effect of a ketone monoester on cardiac PCr/ATP
Study objectivesKetone ingestion will lower cardiac phosphocreatine (PCr)/ATP ratio.
Ethics approval(s)Ethics approval will be sought following trial registration.
Health condition(s) or problem(s) studiedHealthy volunteers
InterventionAfter consent, we will ask participants to fast for 24 hours. During this period, drinking water is allowed and encouraged. Afterwards, we will measure baseline blood ketone levels and perform a Phosphorus Magnetic Resonance Spectroscopy scan (31P MRS) which lasts around 30 minutes. Then, we will ask participants to drink a mix of 25 ml of a ketone monoester and water and repeat the 31P MRS scan and the blood ketone levels measurement. In total, participant involvement lasts around 26 hours.
Intervention typeSupplement
Primary outcome measureCardiac phosphocreatine/ATP (PCr/ATP) ratio assessed using 31P MRS scan after 24 h fasting and 30 minutes after drinking the ketone monester solution
Secondary outcome measuresNone
Overall study start date01/04/2018
Completion date01/08/2019

Eligibility

Participant type(s)Healthy volunteer
Age groupAdult
Lower age limit18 Years
Upper age limit70 Years
SexBoth
Target number of participants15
Key inclusion criteria1. Fluent in English with no communication impairments
2. Willing and able to give informed consent for participation in the study
3. Aged 18-70 years (inclusive)
4. No known medical diagnosis
5. No prescribed medication
6. In the Investigator’s opinion, able and willing to comply with all study requirements
Key exclusion criteria1. Contraindication for undergoing Magnetic Resonance Imaging (MRI), such as metallic implanted devices, shrapnel or claustrophobia
2. Pregnant, lactating or planning to get pregnant
3. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the experiment, or the participant’s ability to participate in the study.
Date of first enrolment01/08/2018
Date of final enrolment01/07/2019

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Oxford Centre for Functional MRI of the Brain
OX3 9DU
United Kingdom

Sponsor information

TdeltaS Ltd
Industry

30 Upper High Street
Thame, Oxfordshire
OX9 3EZ
United Kingdom

Funders

Funder type

Not defined

TdeltaS Ltd

No information available

Results and Publications

Intention to publish date01/08/2020
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe data sharing plans for the current study are unknown and will be made available at a later date.